Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced voting results from its annual and special meeting of shareholders held on Sept. 22, 2026, with 46,452,598 common shares represented, or 63.58% of outstanding shares as of the record date. Shareholders approved changing the company's legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1. This follows the adoption of the Helus Pharma business name on Jan. 5 and reflects the company's anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
Shareholders also appointed Zeifmans LLP as auditor, approved setting the board at eight directors, and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall, and Eric So as directors. The strong shareholder turnout and approval of all resolutions demonstrate confidence in the company's strategic direction as it prepares for the next phase of growth.
The name change is more than symbolic; it aligns the corporate identity with the commercial operating name and underscores the company's focus on bringing its proprietary novel serotonergic agonists (NSAs) to market. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004 in Phase 2 for generalized anxiety disorder. These programs address a large unmet need for people suffering from depression, anxiety, and other mental health conditions.
With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The annual meeting results were disseminated through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. The platform also offers press release enhancement and social media distribution to millions of followers, ensuring broad reach for companies like Helus Pharma.
The shareholder approval of the name change and board slate comes at a pivotal time for Helus Pharma as it advances its pipeline. The transition to a commercial-ready company is a significant milestone that could attract increased investor attention and partnerships. With Breakthrough Therapy Designation for HLP003 and a Phase 2 program for HLP004, Helus Pharma is well-positioned to potentially address critical gaps in mental health treatment. The company's focus on novel serotonergic agonists, which are believed to promote neuroplasticity, sets it apart in the competitive pharmaceutical landscape. As Helus Pharma continues to execute its strategy, the rebranding and board support provide a solid foundation for future growth and value creation.
For full terms of use and disclaimers applicable to content provided by NetworkNewsWire, visit https://www.NetworkNewsWire.com/Disclaimer.
